Barry Greene BS

Barry Greene joined Alnylam in 2003 and brings over 20 years of experience in the healthcare, pharmaceutical, and biotechnology industries. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company's global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADEâ„¢ (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Barry served as Executive Vice President and Chief Business Officer for Mediconsult.com.

Prior to Mediconsult.com, his past experiences include Vice President of Marketing and Customer Services for AstraZeneca formerly Astra Merck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Barry received his B.S. in Industrial Engineering from the University of Pittsburgh and serves as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Board of Acorda Therapeutics, Inc.